All In Biotech

Drug Trial Radar · NCT05065983

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], Aluminum Hydroxide Adjuvanted)

Last checked: Nov 20, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Oct 11, 2021

Primary completion

May 5, 2022

Study completion May 5, 2022

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
Collaborators
Emergent BioSolutions
First posted
Oct 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety and immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine \[CHIKV VLP\], aluminum hydroxide adjuvanted).

Conditions

  • Chikungunya Virus

Interventions

  • CHIKV VLP, adjuvantedBiological

    Adjuvanted formulation includes aluminum hydroxide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CHIKV SNA (Serum Neutralizing Antibody) Seroresponse Rate at Day 22Time frame: 21 days post vaccination
  2. CHIKV SNA GMT (Geometric Mean Titer) at Day 22Time frame: 21 days post vaccination
  3. CHIKV SNA Seroresponse Rates at Days 8, 15, and 57Time frame: 56 days post vaccination
  4. CHIKV SNA GMTs at Days 8, 15, and 57Time frame: 56 days post vaccination
  5. CHIKV ELISA (Enzyme-Linked Immunosorbent Assay) IgG GMTs at Days 8, 15, 22, and 57Time frame: 56 days post vaccination
  6. CHIKV ELISA IgM GMTs at Days 8, 15, 22, and 57Time frame: 56 days post vaccination
  7. Geometric Mean Fold Increase (GMFI) in CHIK SNA Titers at Days 8, 15, 22, and 57Time frame: 56 days post vaccination
  8. GMFI in CHIK ELISA IgG at Days 8, 15, 22, and 57Time frame: 56 days post vaccination
  9. GMFI in CHIK ELISA IgM at Days 8, 15, 22, and 57Time frame: 56 days post vaccination
  10. Number and Percentage of Participants With a CHIKV SNA Titer at or Above Threshold Values at Days 8, 15, 22, and 57Time frame: 56 days post vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johnson County ClinTrials

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.